GreenLight Biosciences Fundraise: US$102M From Morningstar, Others

greenlight biosciences fundraise

Malaysian government’s Xeraya Capital also participated in GreenLight Biosciences’ fundraise

U.S.-based biotechnology company GreenLight Biosciences has raised $102 million in its Series D round fundraise from large Southeast Asian and American investors, the company announced in a statement.

The oversubscribed round was led by Hong Kong-based Morningside Ventures, owned by the Chan family, the real-estate family business behind property developer group Hang Lung, with participation from a host of new and existing investors.

Malaysian government-owned Xeraya Capital also participated in the fundraise via MLS Capital Fund II, a biogreentech fund co-managed by Spruce Capital Partners and Xeraya Capital.

Xeraya Capital had earlier invested in GB’s $17 million ‘special purpose funding round’ to grow production capacity for possible Covid-19 vaccines, including those based ribonucleic acid (RNA).

Other investors in the Series D round included S2G Ventures, Cormorant Asset Management, Continental Grain Company, Fall Line Capital, Tao Capital Partners, Baird Capital (who also participated in the $17 million round), Lewis and Clark Agrifood, and Lupa Systems, all of whom are based in the U.S.

“GreenLight Biosciences’ manufacturing technology can address critical pain points for RNA supply in both agriculture and human health,” Morningside Ventures Investment Advisor and Intellectual Property Counsel Jason Dinges said in the statement.

He added that RNA products are an avenue for innovation in human therapeutics and environment-friendly agriculture.

The fresh capital will be used to expand production of the company’s RNA products, which include new RNA-based therapies, to create sustainable solutions in health sciences and agriculture.

[RNA is a biological macromolecule](https://www.rnasociety.org/what-is-rna#:~:text=Ribonucleic acid%2C or RNA is,DNA makes RNA makes protein”.) that helps synthesize the genetic information present in DNA into proteins. In some cases, RNA can carry viral genetic information and has been connected to human diseases such as heart disease, stroke, and some types of cancer.

The funding will also drive development and commercialization of the company’s sustainable agriculture products. GreenLight Biosciences is expecting to launch its first biopesticide in 2022.

“GreenLight was born from a passion to make our world more sustainable and more equitable,” GreenLight Biosciences Co-founder and CEO Andrey Zarur said in the statement. “We remain steadfast in our commitment to provide bio-based solutions for plant health, human health and animal health, and to make those solutions affordable and accessible.”

The company has been raised capital in a sequence of Series D tranches from 2017, when it first raised a $18 million Series D round in September 2017 led by Fall Line Capital, with five other participating investors including Lewis and Clark Ventures and S2G Ventures.

More recently, it also raised $50 million in a venture round led by S2G Ventures and Baird Capital in January 2019, with participation from five other investors including Tao Capital Partners and Continental Grain Company.

Overall, the 2008-founded company has raised a total corpus of $215 million in eight rounds since 2013.

Header image by Martin Lopez from Pexels

SHARE THIS STORY

Share on facebook
Share on twitter
Share on linkedin
Share on email
Sharon Lewis
Sharon is a Staff Writer at Jumpstart

RELATED POSTS

Is the Corporate Wellness Industry a Total Scam

Is the Corporate Wellness Industry a Total Scam?

Green smoothies, spontaneous getaways and jade rollers have grown into “essentials” for those looking to boost their life. On TikTok, there’s the “that girl” routine urging women to wake up at 5am, do yoga, make an iced coffee and read a book. Over the past year, we have all become projects of self-care. We are all trying to become better versions of ourselves, whatever that may entail. That’s what brands have made note of and are using to their advantage.

Top 5 Memes Sold as NFTs

The Top 5 Memes Sold as NFTs

Oh, to be a viral meme and earn thousands of dollars. From “Bad Luck Brian” to “Success Kid”—the creators and faces of these memes have immortalized themselves on the internet. What’s more? In doing so, they have made a lot of money. Here’s a look at our list of top five memes that sold as NFTs:

What Makes an NFT an Asset

What Makes an NFT an Asset?

Anyone who has heard about NFTs will marvel at the astonishing prices people are willing to pay for them. Recently, the “Side-Eye Chloe” meme sold as an NFT for US$76,377.50, joining many other legendary meme NFTs. But what are NFTs? And why are people willing to bear such an expense to own them?

SleepTech

What Is SleepTech and Does It Work?

Many people nowadays find themselves sleeping for less than the recommended 7 hours each night. Many more struggle to fall asleep, no matter because of external stimulation, stress or distractions. The pandemic has only made matters worse, where reports of insomnia have spiked around the world.

Canva Co-Founder

Canva Co-Founder Becomes the Richest Self-Made Female Billionaire

In a recent valuation, the Australian graphic designing website, Canva, was valued at a whopping US$40 billion. This cements its place as one of the largest privately-owned companies in the world. The company is now the fifth most valuable startup worldwide, closely following SpaceX, Stripe, ByteDance and Klarna.